In this study, we want to see how well a new drug called Quizartinib works for people with Leukemia who do not have a specific mutation called FLT3-ITD. We want to see if this new drug helps improve the condition.
Thank you for your interest, but this study will start enrolling soon.
United States (Nationwide)
Joshua Zeidner
Lineberger Comprehensive Cancer Center
Clinical or Medical
Interventional
Cancer (Leukemia)
24-1672
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
